Phase 1, Open-label, Drug-drug Interaction Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

NCT02080780 Phase 1 COMPLETED Results posted

The purpose of this study is to evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.

Details

Lead sponsor	Ventrus Biosciences, Inc
Phase	Phase 1
Status	COMPLETED
Enrolment	24
Start date	2013-09
Completion	2013-10

Conditions

• CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]

Interventions

• Clarithromycin XL
• 2% Diltiazem

Primary outcomes

• Peak Plasma Concentration (Cmax) of 2% Diltiazem — 9 days
  To evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.

Countries

United States